Hu S, et al. - In this single-center retrospective study, researchers identified possible predictors and to establish a multivariable model for predicting the efficacy of intravenous methylprednisolone (IVMP) therapy in the treatment of moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). The study sample included 302 consecutive patients diagnosed with moderate-to-severe and active TAO who had the full course of IVMP therapy. For managing TAO patients, several suggestions were made, such as early diagnosis and treatment (within 15 months), prompt restoration and maintenance of euthyroidism, particularly meticulous control of thyroid stimulating hormone (TSH) levels (≤ 5 μIU/mL), and regular monitoring of triglyceride levels. To help determine the indication and prognosis of IVMP therapy, a multivariable prediction model has been established and validated.